Kane Biotech Announces Publication of revyve® Wound Gel Article in the International Wound Journal

Rhea-AI Summary

Kane Biotech (KNBIF) announced publication of a peer-reviewed article in the International Wound Journal on revyve Antimicrobial Wound Gel. The study reports a thermo-reversible gel with 99.99%–99.9999% bacterial reductions within 30 minutes, sustained in vitro activity up to 7 days, and porcine biocompatibility results. revyve holds US FDA 510(k) clearance and Health Canada approval, and the paper is first-authored by Kane R&D lead Dr. Jeyachchandran Visvalingam with collaborators from University of Miami.

Positive

• Rapid antimicrobial efficacy: 99.99%–99.9999% bacterial reduction within 30 minutes
• Sustained activity: in vitro antimicrobial effect reported up to 7 days, potentially reducing dressing changes
• Regulatory clearances: US FDA 510(k) clearance and Health Canada approval for revyve

Negative

• Evidence scope limited: reported data are in vitro and porcine wound-healing studies, not large human RCTs

WINNIPEG, Manitoba, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE) (“Kane Biotech” or “Kane”) announces the publication of an article on its revyve^® Antimicrobial wound gel in the International Wound Journal. The article “Wound Healing Property of a Novel Thermo-Reversible Wound Gel With Lasting Antimicrobial and Antibiofilm Activity” is first-authored by Dr. Jeyachchandran Visvalingam, Internal R&D Leader, and includes authors from the Miller School of Medicine, Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery, University of Miami.

Key messages of the article as it relates to Kane’s revyve wound gel include:

• The thermo-reversible gel shifts from a low viscosity liquid to a form-fitting gel at body temperature, then re-liquefies when cooled for easy, atraumatic removal.
  
• revyve demonstrated efficacy against a broad range of wound-related pathogens, including Staphylococcus aureus and Pseudomonas aeruginosa, with a 99.99%–99.9999% reduction in bacterial counts within 30 min.
  
• There was sustained in vitro activity for up to 7 days, potentially reducing the number of dressing changes.
  
• The safety and non-cytotoxicity of the gel were validated through biocompatibility testing and a porcine wound-healing study.

US FDA 510(k) cleared and Health Canada approved revyve Antimicrobial Wound Gel

The International Wound Journal is a peer-reviewed scientific journal focused on research in wound care and wound healing. It publishes original studies, clinical research, and reviews that advance knowledge in wound prevention, treatment, and management.

The article can be viewed here.

“Having our research published in the International Wound Journal underscores the scientific rigor behind revyve technology and provides independent, peer-reviewed validation of the gel’s safety, in vitro performance and clinical potential,” said Interim CEO, Dr. Robert Huizinga. “Recognition in such a respected global wound-care publication strengthens our credibility with clinicians, regulators and commercial partners, and reinforces our commitment to advancing evidence-based solutions that improve patient outcomes.”

About Kane Biotech Inc. (TSX-V:KNE)
Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve^® addresses both biofilms and wound bacteria. revyve^® Antimicrobial Wound Gel, revyve^® Antimicrobial Wound Gel Spray and revyve^® Antimicrobial Skin and Wound Cleanser are all U.S. FDA 510(k) cleared. revyve^® Antimicrobial Wound Gel and revyve^® Antimicrobial Wound Gel Spray are also Health Canada approved. To learn more, visit revyvegel.com or revyvegel.ca.

Join Kane’s Distribution List & Social Media:

To stay informed on the latest developments, sign up for the Company’s email distribution list HERE.

Follow Kane

Website: kanebiotech.com

LinkedIn: https://www.linkedin.com/company/kanebiotech/

Presentations: https://kanebiotech.com/publications-posters/

For more information:
Dr. Robert Huizinga Interim CEO Kane Biotech Inc. rhuizinga@kanebiotech.com  (780) 970-1100	Ray Dupuis Chief Financial Officer      Kane Biotech Inc.  rdupuis@kanebiotech.com  (204) 298-2200

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedarplus.ca. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/32597a8c-e4f5-4846-8ef1-7678003c4724

FAQ

What did Kane Biotech (KNBIF) publish about revyve wound gel on February 20, 2026?

Kane Biotech published a peer-reviewed article describing revyve's thermo-reversible gel, antimicrobial potency, and safety data. According to the company, the paper reports rapid bacterial reductions and sustained in vitro activity with porcine biocompatibility results.

How effective is revyve wound gel against common wound pathogens in the published study (KNBIF)?

The study reports 99.99%–99.9999% reduction in bacterial counts within 30 minutes. According to the company, efficacy was shown against pathogens including Staphylococcus aureus and Pseudomonas aeruginosa in in vitro testing.

Does the revyve publication indicate longer dressing intervals for patients (KNBIF)?

The article reports sustained in vitro activity for up to seven days, which could reduce dressing changes. According to the company, this sustained activity may potentially lower dressing-change frequency, pending clinical validation.

What safety evidence for revyve did Kane Biotech (KNBIF) report in the International Wound Journal?

The paper reports biocompatibility testing and a porcine wound-healing study showing non-cytotoxicity and safety signals. According to the company, these preclinical results support revyve's safety profile prior to broader clinical testing.

Is revyve cleared for use by regulators and how does that affect KNBIF investors?

Revyve holds US FDA 510(k) clearance and Health Canada approval, enabling market access in those jurisdictions. According to the company, these regulatory clearances support commercialization opportunities while clinical adoption and sales remain future drivers.